Blincyto is a trading name of Blinatumomab. Blinatumomab got the FDA approval in 2014 as a second-line treatment medication for Acute Lymphoblastic Leukemia (ALL). Later, this drug molecule also got approval from EMA and has attained breakthrough drug status by the FDA. Indian patients who require Blincyto do not get relevant information related to the price and availability of the drug from the local dealers and pharmacies. Such patients are often misguided by surfing different irrelevant websites and may end up with disappointment. Indian populations who do not easily get Blincyto need to talk with their treating doctor. Patients who already have procured this medicine could provide relevant information from their confident references.
Blincyto specifically recommended for treating Ph-negative replaced ALL. Blinatumomab is safe to use for both pediatric and adult applications. Micromet, a Germany-based Biotechnology Company focused on the research, development, and commercialization of novel biological products for the treatment and control of cancer has first discovered the Blinatumomab molecule. Presently, Amgen, an American multinational biopharmaceutical company makes available Blincyto 38.5mcg globally.
Blincyto is a life-saving drug with multiple clinical benefits. Besides cancer treatment, Blinatumomab is also used as immunotherapy. This single medication gives an overall survival benefit to the patient. Clinical trials have proven the efficacy of Blinatumomab in terms of increasing the overall survival rate. The study result found almost double the median survival rate than the conventional treatment. Currently, Hematologists preferably prescribe Blincyto to patients with ALL. Another clinical research also reported that Blinatumomab offers better overall survival for patients with minimal residual disease (MRD) than bone marrow transplantation or hematopoietic stem cell transplantation.
According to the treatment plan, Indian patients who have a prescription for Blincyto need special patient-level licenses to import the medicine formally. The cost of the Blincyto is the same in India as per the International market price. The small price variation may happen due to the conversion of currency and the global supply chain. The price of Blincyto varies from country to country. Therefore, a patient needs to select the importing country wisely by analyzing the cost factor of the drug.
Professional assistance require for making Blincyto available
Blincyto is a cold chain product that needs temperature maintenance between 2 to 8 degrees during transportation. The drug efficacy would be compromised in case of failure of maintaining the proper temperature range. Patients who need this medication for their personal use require following the guidelines provided by the CDSCO to legally procure the Import Permit. The patient can access the authentic sources that have been experienced in the patient services relating to import medicine for hassle-free access.